文献速递血脂与心血管预防心力衰竭与心肌病

BNT162b2与mRNA-1273第二剂后心肌炎/心包炎风险比较

Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

基于不列颠哥伦比亚COVID-19队列的人群研究,比较第二剂BNT162b2与mRNA-1273后21天内因心肌炎、心包炎或心肌心包炎住院或急诊就诊的风险。

要点

  • mRNA-1273第二剂后心肌炎/心包炎风险约为BNT162b2的2-3倍。
  • 年轻男性(18-39岁)接种mRNA-1273后心肌炎风险显著升高。
  • 总体发生率罕见,但疫苗选择可能需考虑年龄和性别因素。

核心结论

  • 接种第二剂mRNA-1273后心肌炎/心包炎风险约为BNT162b2的2-3倍,但在所有人群中仍属罕见。

研究设计与样本

  • 基于不列颠哥伦比亚COVID-19队列(BCC19C)的人群队列研究,暴露为第二剂mRNA疫苗,结局为接种后21天内因心肌炎、心包炎或心肌心包炎住院或急诊就诊,采用多变量逻辑回归分析。

主要发现

  • mRNA-1273组心肌炎发生率为35.6/百万剂(95%CI 24.1-50.5),BNT162b2组为12.6/百万剂(95%CI 8.4-18.2)。
  • mRNA-1273组心包炎发生率为22.9/百万剂(95%CI 14.0-35.4),BNT162b2组为9.4/百万剂(95%CI 5.8-14.4)。
  • mRNA-1273相比BNT162b2的心肌炎调整OR为2.78(95%CI 1.67-4.62),心包炎为2.42(95%CI 1.31-4.46),心肌心包炎为2.63(95%CI 1.76-3.93)。
  • 男性中心肌炎关联更强(aOR 3.21,95%CI 1.77-5.83),18-39岁年龄组aOR为5.09(95%CI 2.68-9.66)。

关键数值与推荐

  • mRNA-1273第二剂后心肌炎发生率为35.6/百万剂,BNT162b2为12.6/百万剂。
  • mRNA-1273相比BNT162b2心肌炎调整OR 2.78(95%CI 1.67-4.62)。
  • 18-39岁人群接种mRNA-1273后心肌炎调整OR 5.09(95%CI 2.68-9.66)。

临床怎么用

  • 在为年轻男性选择mRNA疫苗时,可参考此风险差异进行个体化评估。
  • 接种mRNA疫苗后21天内需警惕心肌炎/心包炎症状,尤其是年轻男性。

局限性

  • 原文摘要未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postmarketing evaluations have linked myocarditis to COVID-19 mRNA vaccines. However, few population-based analyses have directly compared the safety of the 2 mRNA COVID-19 vaccines. OBJECTIVES: This study aimed to compare the risk of myocarditis, pericarditis, and myopericarditis between BNT162b2 and mRNA-1273. METHODS: We used data from the British Columbia COVID-19 Cohort (BCC19C), a population-based cohort study. The exposure was the second dose of an mRNA vaccine. The outcome was diagnosis of myocarditis, pericarditis, or myopericarditis during a hospitalization or an emergency department visit within 21 days of the second vaccination dose. We performed multivariable logistic regression to assess the association between vaccine product and the outcomes of interest. RESULTS: The rates of myocarditis and pericarditis per million second doses were higher for mRNA-1273 (n = 31, rate 35.6; 95% CI: 24.1-50.5; and n = 20, rate 22.9; 95% CI: 14.0-35.4, respectively) than BNT162b2 (n = 28, rate 12.6; 95% CI: 8.4-18.2 and n = 21, rate 9.4; 95% CI: 5.8-14.4, respectively). mRNA-1273 vs BNT162b2 had significantly higher odds of myocarditis (adjusted OR [aOR]: 2.78; 95% CI: 1.67-4.62), pericarditis (aOR: 2.42; 95% CI: 1.31-4.46) and myopericarditis (aOR: 2.63; 95% CI: 1.76-3.93). The association between mRNA-1273 and myocarditis was stronger for men (aOR: 3.21; 95% CI: 1.77-5.83) and younger age group (18-39 years; aOR: 5.09; 95% CI: 2.68-9.66). CONCLUSIONS: Myocarditis/pericarditis following mRNA COVID-19 vaccines is rare, but we observed a 2- to 3-fold higher odds among individuals who received mRNA-1273 vs BNT162b2. The rate of myocarditis following mRNA-1273 receipt is highest among younger men (age 18-39 years) and does not seem to be present at older ages. Our findings may have policy implications regarding the choice of vaccine offered.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Naveed Z, Li J, Wilton J, et al. Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines. J Am Coll Cardiol. 2022. PMID: 36357091. doi:10.1016/j.jacc.2022.08.799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。